[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615079":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":24,"locations":30,"responsibleParty":56,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":11,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":11,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Indiana University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Medtronic 780G group","EXPERIMENTAL",null,[13],"Device: Medtronic 780G AID",{"label":15,"type":16,"description":17,"interventionNames":11},"Usual care","NO_INTERVENTION","Participants will continue either multiple daily injections or non-AID insulin pumps",[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DEVICE","Medtronic 780G AID","Participants in Medtronic AID treatment group will use it for three months",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Sana Kalaji","CONTACT","317-278-6017","skalaji@iu.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Indiana University Health, Univeristy hospital","RECRUITING","Indianapolis","Indiana","46202","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-86.15804,39.76838,{"lat":43,"lon":42},[46,50,52,54],{"name":47,"role":27,"phone":48,"phoneExt":11,"email":49},"Zunera Tariq, MD","317-278-0907","tariqz@iu.edu",{"name":51,"role":27,"phone":28,"phoneExt":11,"email":49},"Viral Shah, MD",{"name":51,"role":53,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":47,"role":55,"phone":11,"phoneExt":11,"email":11},"SUB_INVESTIGATOR",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Viral N. Shah","Principal Investigator",[61],{"name":62,"class":63},"Medtronic","INDUSTRY","100615079","to-study-the-efficacy-and-safety-of-medtronic-780g-insulin-pump-in-people-with-gastroparesis-and-type-1-diabetes-100615079",false,"NCT07287943","To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.","Efficacy and Safety of Medtronic 780G Automated Insulin Delivery System in Adults With Type 1 Diabetes and Gastroparesis","Inclusion criteria\n\n* Age ≥18 years\n* Diagnosis of T1D for at least 12 months with stable insulin regimen for at least 2 months\n* HbA1c ≥8.0%\n* Diagnosis of gastroparesis per National Institute of Health (NIH) definition\n* Willing to use Medtronic 780G system either with Simplera CGM.\n* Ability to provide informed consent before any trial-related activities\n* If randomized to usual care group and on an insulin pump already, should be willing to use pump in manual mode only for the duration of the study\n\nExclusion criteria\n\n* Age \\\u003C18 years\n* Current use of inhaled insulin (Afrezza)\n* Patients with T1D using any glucose lowering medications other than insulin at the time of screening\n* Pregnancy, breast feeding, or wanting to become pregnant\n* Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (\\>4 weeks continuously), during the study period\n* History of gastric outlet obstruction or other gastrointestinal structural abnormalities\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 or on dialysis\n* History of SH in the previous 3 months\n* History of two or more episodes DKA requiring hospitalization in the past 12 months\n* Any medical (such as severe cardiovascular disease, malignancy, chronic liver disease) or psychosocial conditions that make a person unfit for the study at the discretion of investigators\n* Use of investigational drugs within 5 half-lives prior to screening\n* Current use of cannabis or history of cannabinoid hyperemesis syndrome","ALL","18 Years",{"count":74,"type":75},34,"ESTIMATED","INTERVENTIONAL",[78],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.",[81,82],"Type 1 Diabetes","Gastroparesis Due to Diabetes Mellitus Type I",[84,85],"type 1 diabetes","gastroparesis","2026-02-14",{"date":88,"type":89},"2026-02-18","ACTUAL",{"date":91,"type":89},"2026-02-09",{"date":93,"type":75},"2026-12-01",{"name":58,"class":6},1]